Pharmaron Beijing (SZSE:300759) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥12.3b (up 6.4% from FY 2023).
- Net income: CN¥1.79b (up 12% from FY 2023).
- Profit margin: 15% (in line with FY 2023).
- EPS: CN¥1.01 (up from CN¥0.90 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Pharmaron Beijing Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
The primary driver behind last 12 months revenue was the Laboratory Services segment contributing a total revenue of CN¥7.05b (57% of total revenue). Notably, cost of sales worth CN¥8.09b amounted to 66% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CN¥1.63b (66% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥74.1m. Explore how 300759's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.
Performance of the Chinese Life Sciences industry.
The company's share price is broadly unchanged from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Pharmaron Beijing's balance sheet.
Valuation is complex, but we're here to simplify it.
Discover if Pharmaron Beijing might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.